333 related articles for article (PubMed ID: 1972442)
1. Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies.
Atzpodien J; Körfer A; Franks CR; Poliwoda H; Kirchner H
Lancet; 1990 Jun; 335(8704):1509-12. PubMed ID: 1972442
[TBL] [Abstract][Full Text] [Related]
2. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experience.
Kirchner H; Körfer A; Palmer PA; Evers P; De Riese W; Knüver-Hopf J; Hadam M; Goldman U; Franks CR; Poliwoda H
Mol Biother; 1990 Sep; 2(3):145-54. PubMed ID: 2222898
[TBL] [Abstract][Full Text] [Related]
4. The out-patient use of recombinant human interleukin-2 and interferon alfa-2b in advanced malignancies.
Atzpodien J; Kirchner H
Eur J Cancer; 1991; 27 Suppl 4():S88-91; discussion S92. PubMed ID: 1799491
[TBL] [Abstract][Full Text] [Related]
5. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
6. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.
Atzpodien J; Kirchner H; Körfer A; Hadam M; Schomburg A; Menzel T; Deckert M; Franzke A; Volkenandt M; Dallmann I
Tumour Biol; 1993; 14(6):354-9. PubMed ID: 8265981
[TBL] [Abstract][Full Text] [Related]
7. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.
Atzpodien J; Lopez Hänninen E; Kirchner H; Bodenstein H; Pfreundschuh M; Rebmann U; Metzner B; Illiger HJ; Jakse G; Niesel T
J Clin Oncol; 1995 Feb; 13(2):497-501. PubMed ID: 7844611
[TBL] [Abstract][Full Text] [Related]
8. Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous alpha-interferon.
Besana C; Borri A; Bucci E; Citterio G; Di Lucca G; Fortis C; Matteucci P; Tognella S; Tresoldi M; Baiocchi C
Eur J Cancer; 1994; 30A(9):1292-8. PubMed ID: 7999416
[TBL] [Abstract][Full Text] [Related]
9. Hematotoxicity of interleukin-2 in man: clinical effects and comparison of various treatment regimens.
Schomburg A; Kirchner H; Atzpodien J
Acta Haematol; 1993; 89(3):119-31. PubMed ID: 8362600
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study.
Facendola G; Locatelli MC; Pizzocaro G; Piva L; Pegoraro C; Pallavicini EB; Signaroldi A; Meregalli M; Lombardi F; Beretta GD
Br J Cancer; 1995 Dec; 72(6):1531-5. PubMed ID: 8519672
[TBL] [Abstract][Full Text] [Related]
11. Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo.
Schneekloth C; Körfer A; Hadam M; Lopez Hänninen E; Menzel T; Schomburg A; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Acta Haematol; 1993; 89(1):13-21. PubMed ID: 7683166
[TBL] [Abstract][Full Text] [Related]
12. Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: evidence of a risk/benefit advantage of subcutaneous therapy.
Schomburg A; Kirchner H; Atzpodien J
J Cancer Res Clin Oncol; 1993; 119(12):745-55. PubMed ID: 8408187
[TBL] [Abstract][Full Text] [Related]
13. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-2 in combination with interferon-alpha in disseminated malignant melanoma and advanced renal cell carcinoma. A phase I/II study.
Bergmann L; Weidmann E; Mitrou PS; Runne U; Keilholz U; Bartsch HH; Franks CR
Onkologie; 1990 Apr; 13(2):137-40. PubMed ID: 2197585
[TBL] [Abstract][Full Text] [Related]
15. [Combination therapy with recombinant interferon alpha-21 (rIFN alpha 2a) and recombinant interleukin 2 (rIL-2) in metastatic renal cell cancer].
Jurincic-Winkler C; Horlbeck R; Klippel KF
Wien Klin Wochenschr; 1993; 105(10):271-6. PubMed ID: 8517056
[TBL] [Abstract][Full Text] [Related]
16. Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma.
Olencki T; Peereboom D; Wood L; Budd GT; Novick A; Finke J; McLain D; Elson P; Bukowski RM
J Cancer Res Clin Oncol; 2001 May; 127(5):319-24. PubMed ID: 11355147
[TBL] [Abstract][Full Text] [Related]
17. Hepatic and serologic toxicity of systemic interleukin-2 and/or interferon-alpha. Evidence of a risk-benefit advantage of subcutaneous therapy.
Schomburg A; Kirchner H; Lopez-Hänninen E; Menzel T; Rudolph P; Körfer A; Fenner M; Poliwoda H; Atzpodien J
Am J Clin Oncol; 1994 Jun; 17(3):199-209. PubMed ID: 7910716
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
[TBL] [Abstract][Full Text] [Related]
19. Treatment of metastatic renal cell cancer patients with recombinant subcutaneous human interleukin-2 and interferon-alpha.
Atzpodien J; Körfer A; Palmer PA; Franks CR; Poliwoda H; Kirchner H
Ann Oncol; 1990 Sep; 1(5):377-8. PubMed ID: 2261378
[TBL] [Abstract][Full Text] [Related]
20. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
